Fresenius Kabi and AABB Announce 21st Annual Blood Collectors Week, September 6–12, 2026, Honoring Lifesaving Blood Collection Professionals

National Blood Collectors Week, 2026

• Fresenius Kabi and the Association for the Advancement of Blood & Biotherapies (AABB) announced the 21st annual Blood Collectors Week, Sept. 6-12.
• Blood Collectors Week celebrates the professionals who help ensure access to a safe, high-quality blood supply.
• Nearly 200 blood collection facilities across the United States are expected to participate in Blood Collectors Week through recognition events, social media engagement, and employee appreciation activities.

LAKE ZURICH, Ill. & BETHESDA, Md.--(BUSINESS WIRE)--Fresenius Kabi and the Association for the Advancement of Blood & Biotherapies (AABB) announced today the launch of the 21st annual Blood Collectors Week, taking place September 6–12, 2026. The annual recognition week celebrates the blood collection professionals whose expertise and dedication help ensure patients across the country have access to safe, high-quality blood and blood components.

Blood Collectors Week honors the essential professionals who serve as a critical link between donors and patients, including phlebotomists, apheresis operators, donor recruiters, technicians, drivers, and medical directors. Through their daily work, these individuals play a vital role in maintaining a reliable blood supply and supporting patient care in hospitals and communities nationwide.

Co-created and sponsored by Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, and AABB, an international association representing individuals and institutions involved in the field of transfusion medicine and biotherapies, Blood Collectors Week highlights both the technical skill and compassion required in blood collection.

“Blood collection professionals make a difference every day, often behind the scenes, by helping ensure patients receive the blood products they need at critical moments,” said Eddie Kubo, Senior Vice President, MedTech Commercial Operations, North America at Fresenius Kabi. “Fresenius Kabi is honored to support Blood Collectors Week and to recognize the individuals whose commitment and expertise are foundational to patient care.”

“Blood Collectors Week is an important opportunity to recognize the people whose work makes blood transfusion possible,” said Debra BenAvram, FASAE, CAE, chief executive officer of AABB. “Blood collectors’ dedication to safety, quality and donor care is essential to ensuring a safe, stable and available blood supply. AABB is proud to partner with Fresenius Kabi to help shine a light on these professionals and the life-saving work they do every day.”

Nearly 200 blood collection facilities across the United States are expected to participate in Blood Collectors Week through recognition events, social media engagement, and employee appreciation activities. A list of participating centers is available at https://bloodcollectors.org/join-the-community.

Blood collection professionals are encouraged to visit bloodcollectors.org to share what motivates them in their work and to connect with peers across the community. Everyone is invited to join the celebration by following @bloodcollectors on X (formerly Twitter) and using the hashtags #BloodCollectorsWeek and #SavingLives to show appreciation and support.

To learn more about Blood Collectors Week, find resources to participate, or discover how to donate blood, visit bloodcollectors.org.

About Fresenius Kabi

Fresenius Kabi is part of the global healthcare company Fresenius and specializes in lifesaving medicines, medical technologies, and services for critically and chronically ill patients. With more than 41,000 employees and present in over 100 countries, Fresenius Kabi’s broad portfolio enables access to high-quality products across emergency medicine, surgery, oncology, intensive care, and at home – reaching around 450 million patients each year.

Through complementary business areas, Fresenius Kabi offers highly complex biopharmaceuticals for the treatment of cancer, autoimmune and endocrine diseases; leading enteral, parenteral and homecare solutions within medical nutrition; innovative medical technology including infusion pumps, cell and gene therapy devices, disposables and blood collection systems; and intravenous generic drugs and fluids that are vital to the work of healthcare providers globally.

For more information, please visit www.fresenius-kabi.com.

About Fresenius

Fresenius (XFRA: FRE, OTC: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, clinical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27 million patients annually.

With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025.

For more information, visit www.fresenius.com and follow Fresenius on LinkedIn.

About AABB

AABB is an international, not-for-profit association representing individuals and institutions involved in the field of transfusion medicine and biotherapies. The association is committed to improving health through the development and delivery of standards, accreditation and educational programs that focus on optimizing patient and donor care and safety. AABB membership includes physicians, nurses, scientists, researchers, administrators, medical technologists and other health care providers. AABB members are located in more than 80 countries and AABB accredits institutions in more than 50 countries. To learn more about AABB, visit http://www.aabb.org.